LLY

996.4

-0.46%↓

JNJ

243

-0.23%↓

ABBV

228.13

+0.39%↑

NVS

155.63

-3.52%↓

AZN

192.84

-1.3%↓

LLY

996.4

-0.46%↓

JNJ

243

-0.23%↓

ABBV

228.13

+0.39%↑

NVS

155.63

-3.52%↓

AZN

192.84

-1.3%↓

LLY

996.4

-0.46%↓

JNJ

243

-0.23%↓

ABBV

228.13

+0.39%↑

NVS

155.63

-3.52%↓

AZN

192.84

-1.3%↓

LLY

996.4

-0.46%↓

JNJ

243

-0.23%↓

ABBV

228.13

+0.39%↑

NVS

155.63

-3.52%↓

AZN

192.84

-1.3%↓

LLY

996.4

-0.46%↓

JNJ

243

-0.23%↓

ABBV

228.13

+0.39%↑

NVS

155.63

-3.52%↓

AZN

192.84

-1.3%↓

Search

Champions Oncology Inc

Deschisă

SectorSănătate

5.89 3.15

Rezumat

Modificarea prețului

24h

Curent

Minim

5.66

Maxim

5.8100000000000005

Indicatori cheie

By Trading Economics

Venit

702K

236K

Vânzări

1M

15M

P/E

Medie Sector

35.118

61.417

Marjă de profit

1.57

Angajați

213

EBITDA

1.1M

612K

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+103.39% upside

Dividende

By Dow Jones

Următoarele câștiguri

12 mar. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-25M

83M

Deschiderea anterioară

2.74

Închiderea anterioară

5.89

Sentimentul știrilor

By Acuity

50%

50%

146 / 351 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Champions Oncology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 mar. 2026, 20:38 UTC

Câștiguri

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10 mar. 2026, 23:57 UTC

Market Talk

Global Equities Roundup: Market Talk

10 mar. 2026, 23:57 UTC

Market Talk

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10 mar. 2026, 23:47 UTC

Market Talk

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10 mar. 2026, 23:37 UTC

Achiziții, Fuziuni, Preluări

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10 mar. 2026, 23:37 UTC

Achiziții, Fuziuni, Preluări

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10 mar. 2026, 23:37 UTC

Achiziții, Fuziuni, Preluări

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10 mar. 2026, 23:37 UTC

Achiziții, Fuziuni, Preluări

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10 mar. 2026, 23:35 UTC

Market Talk
Evenimente importante

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10 mar. 2026, 23:06 UTC

Câștiguri

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10 mar. 2026, 22:51 UTC

Evenimente importante

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10 mar. 2026, 21:39 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10 mar. 2026, 21:21 UTC

Câștiguri

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10 mar. 2026, 21:15 UTC

Câștiguri

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10 mar. 2026, 21:15 UTC

Achiziții, Fuziuni, Preluări

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10 mar. 2026, 21:14 UTC

Câștiguri

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10 mar. 2026, 21:13 UTC

Câștiguri

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10 mar. 2026, 21:12 UTC

Câștiguri

Franco-Nevada 4Q Rev $597.3M >FNV

10 mar. 2026, 21:12 UTC

Câștiguri

Franco-Nevada 4Q EPS $1.90

10 mar. 2026, 20:57 UTC

Câștiguri

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar. 2026, 20:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

10 mar. 2026, 20:44 UTC

Câștiguri

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar. 2026, 20:34 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

10 mar. 2026, 20:34 UTC

Market Talk
Câștiguri

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10 mar. 2026, 20:23 UTC

Câștiguri

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar. 2026, 20:16 UTC

Câștiguri

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10 mar. 2026, 20:14 UTC

Câștiguri

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10 mar. 2026, 20:14 UTC

Câștiguri

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10 mar. 2026, 20:13 UTC

Câștiguri

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10 mar. 2026, 20:12 UTC

Câștiguri

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Comparație

Modificare preț

Champions Oncology Inc Așteptări

Obiectiv de preț

By TipRanks

103.39% sus

Prognoză pe 12 luni

Medie 12 USD  103.39%

Maxim 12 USD

Minim 12 USD

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruChampions Oncology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

1 ratings

1

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

5.77 / 7.61Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Very Strong Bearish Evidence

Termen lung

Strong Bearish Evidence

Sentiment

By Acuity

146 / 351 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Champions Oncology Inc

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
help-icon Live chat